Azenta Life Science, headquartered in the United States, is a leading provider in the life sciences industry, specialising in sample management and genomic services. Founded in 2021, the company has quickly established itself as a key player, offering innovative solutions that streamline research and development processes for biopharmaceutical and academic institutions. With a focus on biobanking, sample logistics, and genomic analysis, Azenta Life Science distinguishes itself through its advanced technology and commitment to quality. The company’s core services include automated sample storage, data management, and comprehensive genomic services, all designed to enhance efficiency and accuracy in scientific research. Recognised for its robust market position, Azenta Life Science continues to achieve significant milestones, contributing to advancements in personalised medicine and drug discovery. Its dedication to innovation and customer satisfaction solidifies its reputation as a trusted partner in the life sciences sector.
How does Azenta Life Science's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Azenta Life Science's score of 17 is higher than 61% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Azenta Life Sciences reported total carbon emissions of approximately 14,399,000 kg CO2e for Scope 1 and about 10,565,000 kg CO2e for Scope 2, resulting in a combined total of around 24,964,000 kg CO2e. This reflects a slight increase in Scope 1 emissions from 12,765,000 kg CO2e in 2022, while Scope 2 emissions decreased from approximately 13,492,000 kg CO2e in the previous year. Azenta has established ambitious climate commitments, aiming to reduce its Scope 1 and 2 greenhouse gas emissions by 55% by 2033, using 2022 as the baseline year. This near-term target underscores the company's dedication to addressing its carbon footprint. Furthermore, Azenta is committed to achieving net-zero emissions across all scopes by 2050, aligning with industry standards for climate action. These initiatives position Azenta Life Sciences as a proactive player in the pharmaceuticals, biotechnology, and life sciences sector, demonstrating a commitment to sustainability and responsible environmental stewardship.
Access structured emissions data, company-specific emission factors, and source documents
Add to project2022 | 2023 | |
---|---|---|
Scope 1 | 12,765,000 | 00,000,000 |
Scope 2 | 13,492,000 | 00,000,000 |
Scope 3 | - | - |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Azenta Life Science is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.